Elmind Capital, LP
Long book
$352.2M
Q1 2026
Positions
34
Top-10 weight
69%
concentration
Last quarter
+10.4%
SPY +14.8%
Turnover
11%
of book per quarter
Strategy in plain words
auto-generated from filingsElmind Capital, LP is a concentrated fundamental stock-picker, specialised in healthcare (92% of the long book), running a $352.2M US long book across 34 positions.
The portfolio is concentrated: the top 10 names carry 69% of the portfolio. Turnover is modest: positions are typically held for years. Current anchor positions: COGENT BIOSCIENCES INC, SYNDAX PHARMACEUTICALS INC, CELLDEX THERAPEUTICS INC, CYTOMX THERAPEUTICS INC, KALVISTA PHARMACEUTICALS INC.
We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
+5.3%
Q1 2026
+10.4%
Sector allocation
Healthcare 86%
Materials 8%
Other 7%
Long book by quarter
What does Elmind Capital, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| COGT COGENT BIOSCIENCES INC | Healthcare | 1.2M | $45.1M | 12.8% | Held |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.9M | $43.3M | 12.3% | Held |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 865.0K | $27.4M | 7.8% | Held |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 4.5M | $21.4M | 6.1% | +550.0% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 1.0M | $20.6M | 5.8% | +27.5% |
| CGON CG ONCOLOGY INC | Healthcare | 291.8K | $19.7M | 5.6% | -40.8% |
| VERA VERA THERAPEUTICS INC | Healthcare | 482.5K | $19.4M | 5.5% | Held |
| PCVX VAXCYTE INC | Healthcare | 316.5K | $18.4M | 5.2% | +8.6% |
| PHVS PHARVARIS NV | Healthcare | 475.8K | $13.4M | 3.8% | Held |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 350.0K | $13.4M | 3.8% | Held |
| BEAM BEAM THERAPEUTICS INC | Healthcare | 476.3K | $11.4M | 3.2% | Held |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 534.9K | $10.5M | 3.0% | -37.7% |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.0M | $9.5M | 2.7% | -53.5% |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 15.0K | $8.9M | 2.5% | +36.4% |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 530.0K | $7.5M | 2.1% | +71.0% |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 460.0K | $7.1M | 2.0% | Held |
| MBX MBX BIOSCIENCES INC | Healthcare | 211.0K | $6.3M | 1.8% | Held |
| KRYS KRYSTAL BIOTECH INC | Healthcare | 22.0K | $5.7M | 1.6% | Held |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 536.9K | $5.3M | 1.5% | Held |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 177.6K | $5.3M | 1.5% | +61.5% |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 38.0K | $4.0M | 1.1% | Held |
| URGN UROGEN PHARMA LTD | Healthcare | 220.0K | $4.0M | 1.1% | +120.0% |
| ALMS ALUMIS INC | Healthcare | 130.0K | $2.9M | 0.8% | New |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 47.0K | $2.7M | 0.8% | -42.7% |
| DSGN DESIGN THERAPEUTICS INC | Healthcare | 207.9K | $2.2M | 0.6% | Held |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 50.0K | $2.0M | 0.6% | Held |
| ALEC ALECTOR INC | Healthcare | 900.0K | $1.9M | 0.5% | Held |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 112.0K | $1.6M | 0.4% | Held |
| ENGN enGene Therapeutics Inc | Healthcare | 210.0K | $1.4M | 0.4% | Held |
| WVE WAVE LIFE SCIENCES LTD | Healthcare | 177.8K | $1.3M | 0.4% | -60.3% |
| SUPN SUPERNUS PHARMACEUTICALS INC | Healthcare | 20.0K | $1.0M | 0.3% | Held |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 10.0K | $315K | 0.1% | -66.7% |